These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 2504896

  • 21. Does short-course induction with OKT3 improve outcome after heart transplantation? A randomized trial.
    Kobashigawa JA, Stevenson LW, Brownfield E, Moriguchi JD, Kawata N, Hamilton M, Minkely R, Drinkwater D, Laks H.
    J Heart Lung Transplant; 1993; 12(2):205-8. PubMed ID: 8476892
    [Abstract] [Full Text] [Related]

  • 22. Independent risk factors predicting acute graft rejection in cardiac transplant recipients treated by triple drug immunosuppression.
    Laufer G, Miholic J, Laczkovics A, Wollenek G, Holzinger C, Hajek-Rosenmeier A, Wuzl G, Schreiner W, Buxbaum P, Wolner E.
    J Thorac Cardiovasc Surg; 1989 Dec; 98(6):1113-21. PubMed ID: 2586129
    [Abstract] [Full Text] [Related]

  • 23. A prospective randomized trial of pretransfusion/azathioprine/prednisone versus cyclosporine/prednisone immunosuppression in cardiac transplant recipients: preliminary results.
    Barnhart GR, Hastillo A, Goldman MH, Szentpetery S, Wolfgang TC, Mohanakumar T, Katz MR, Rider S, Hanrahan J, Lower RR.
    Circulation; 1985 Sep; 72(3 Pt 2):II227-30. PubMed ID: 3896555
    [Abstract] [Full Text] [Related]

  • 24. The duration of administration of monoclonal antibody OKT3 for induction immunosuppression after heart transplantation.
    Aleksic I, Freimark D, Blanche C, Czer LS, Dalichau H, Valenza M, Takkenberg JJ, Trento A.
    Thorac Cardiovasc Surg; 1997 Aug; 45(4):190-5. PubMed ID: 9323821
    [Abstract] [Full Text] [Related]

  • 25. OKT3 prophylaxis in cadaveric kidney transplant recipients with delayed graft function.
    Cohen DJ, Benvenisty AI, Cianci J, Hardy MA.
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):19-27. PubMed ID: 2510507
    [Abstract] [Full Text] [Related]

  • 26. Antilymphocyte induction immunosuppression in the post-Minnesota anti-lymphocyte globulin era: incidence of renal dysfunction and delayed graft function. A single center experience.
    Malinow L, Walker J, Klassen D, Oldach D, Schweitzer E, Bartlett ST, Weir MR.
    Clin Transplant; 1996 Jun; 10(3):237-42. PubMed ID: 8826659
    [Abstract] [Full Text] [Related]

  • 27. A randomized prospective trial of prophylactic immunosuppression with ATG-fresenius versus OKT3 after renal transplantation.
    Bock HA, Gallati H, Zürcher RM, Bachofen M, Mihatsch MJ, Landmann J, Thiel G.
    Transplantation; 1995 Mar 27; 59(6):830-40. PubMed ID: 7701577
    [Abstract] [Full Text] [Related]

  • 28. Comparison of Minnesota antilymphocyte globulin and OKT3 for induction of immunosuppression in renal transplant patients.
    Light JA, Khawand N, Ali A, Brems W, Aquino A.
    Transplant Proc; 1989 Feb 27; 21(1 Pt 2):1738-40. PubMed ID: 2652569
    [Abstract] [Full Text] [Related]

  • 29. Influence of induction therapy on rejection and survival in heart transplantation.
    Almenar L, García-Palomar C, Martínez-Dolz L, Chamorro C, Moro J, Zorio E, Arnau MA, Rueda J, Osa A, Cardo ML.
    Transplant Proc; 2005 Nov 27; 37(9):4024-7. PubMed ID: 16386616
    [Abstract] [Full Text] [Related]

  • 30. The effects of HLA mismatching and immunosuppressive therapy on early rejection outcome in pediatric heart transplant recipients.
    Herzberg GZ, Rossi AF, Courtney M, Gelb BD.
    J Heart Lung Transplant; 1998 Dec 27; 17(12):1195-200. PubMed ID: 9883760
    [Abstract] [Full Text] [Related]

  • 31. Orthoclone OKT3 treatment of acute renal allograft rejection in patients receiving maintenance cyclosporine therapy.
    Hirsch RL, Layton PC, Barnes LA, Kremer AB, Goldstein G.
    Transplant Proc; 1987 Apr 27; 19(2 Suppl 1):32-6. PubMed ID: 3105138
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Immunologic monitoring with Orthoclone OKT3 therapy.
    Schroeder TJ, First MR, Hurtubise PE, Marmer DJ, Martin DM, Mansour ME, Melvin DB.
    J Heart Transplant; 1989 Apr 27; 8(5):371-80. PubMed ID: 2529358
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Two low-dose OKT3 induction regimens following renal transplantation--clinical experience at a single center.
    Oh HK, Provenzano R, Tayeb J, Satmary N, Jones B.
    Clin Transplant; 1998 Aug 27; 12(4):343-7. PubMed ID: 9686329
    [Abstract] [Full Text] [Related]

  • 37. Antithymocyte gamma globulin, low-dosage cyclosporine, and tapering steroids as an immunosuppressive regimen to avoid early kidney failure in heart transplantation.
    Deeb GM, Kolff J, McClurken JB, Dunn J, Balsara R, Ochs R, Badellino M, Hollander T, Eldridge C, Clancey M.
    J Heart Transplant; 1987 Aug 27; 6(2):79-83. PubMed ID: 3305833
    [Abstract] [Full Text] [Related]

  • 38. Neoquadruple induction with antithymocyte globulin/azathioprine/cyclosporine/prednisolone in simultaneous pancreas and kidney transplant recipients: 8.5-year results.
    Schulz T, Kapischke M, Busing M.
    Transplant Proc; 2005 May 27; 37(4):1815-7. PubMed ID: 15919475
    [Abstract] [Full Text] [Related]

  • 39. [Acute rejection in cadaveric renal transplantation under cyclosporine based therapy. Analysis of the risk factors and its influence on chronic dysfunction].
    Mota A.
    Acta Med Port; 2004 May 27; 17(1):8-14. PubMed ID: 15636737
    [Abstract] [Full Text] [Related]

  • 40. The natural history of renal function following orthotopic heart transplant.
    Al Aly Z, Abbas S, Moore E, Diallo O, Hauptman PJ, Bastani B.
    Clin Transplant; 2005 Oct 27; 19(5):683-9. PubMed ID: 16146562
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.